Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1845
Completed
3
100.0%
No approval data available
- RCSI researchers have published the first preclinical proof-of-concept for an mRNA vaccine targeting neuroblastoma, the deadliest childhood cancer. - The vaccine, delivered via self-assembling peptide nanoparticles targeting Glypican 2 (GPC2), reduced tumor volume by 70% and delayed tumor development by 10–11 days in murine models. - Neuroblastoma accounts for 15% of all pediatric cancer deaths, and 80% of high-risk patients show no significant response to current standard therapies. - The modular "LEGO-like" vaccine design and GPC2's presence across multiple cancers suggest broader therapeutic potential beyond neuroblastoma.
- A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%. - The CO.21 Challenge study, published in the New England Journal of Medicine, is the first clinical trial designed specifically to test whether exercise can improve cancer survival outcomes. - Researchers emphasize that exercise should now be considered a standard treatment for colon cancer rather than just a quality-of-life intervention, requiring integration into healthcare systems. - The study involved patients with Stage 3 or high-risk Stage 2 colon cancer who completed surgery and chemotherapy, with participants following a 3-year structured exercise program of 2.5 hours weekly moderate-intensity activity.
